Former Moderna Chief Development Officer Melanie Ivarsson OBE Joins PhaseV's Scientific Advisory Board

Veteran Global Clinical Leader, Honored for Helping Develop One of the First COVID Vaccines, to Support Rollout of PhaseV's New AI Platform for Clinical Development

BOSTON, July 1, 2025 /PRNewswire/ -- PhaseV, a leader in AI/ML-driven clinical development, today announced the appointment of Melanie Ivarsson OBE, PhD, to the company's scientific advisory board. A veteran drug development leader, Dr. Ivarsson most recently served as Senior Vice President and Chief Development Officer at Moderna, where she was honored as an Officer of the Order of the British Empire (OBE) for her leadership in the development of one of the first COVID-19 vaccinations.

Dr. Ivarsson's appointment coincides with the launch of PhaseV's new ClinOps platform, a next-generation AI solution to optimize clinical trial operations through enhanced site selection and performance monitoring.

"PhaseV's groundbreaking AI-driven platform will redefine how clinical trials are designed and executed, with speed, accuracy, and new levels of insight that the industry urgently needs," said Dr. Ivarsson. "It's a privilege to join such an innovative, ambitious team driving a true paradigm shift in how we bring new therapies to market."

Dr. Ivarsson brings almost three decades of experience leading drug development and clinical operations. Prior to Moderna, she served as Head of Global Clinical Operations at Japanese pharmaceutical manufacturer Takeda, where she oversaw trials across oncology, neuroscience, rare diseases, GI and plasma-derived therapies. She spent almost a decade at Pfizer, holding a variety of senior leadership positions responsible for the delivery of clinical programs. Before Pfizer, she was part of the early clinical development group at Eli Lilly.

"Dr. Ivarsson's decision to join PhaseV is a powerful endorsement of the impact of our vertical AI solutions for biopharma," said Raviv Pryluk, PhD, CEO and Co-founder of PhaseV. "Her track record leading complex and high-impact global clinical programs, including the first COVID vaccinations, brings unmatched expertise to our mission. Her insights will be invaluable as we continue to expand our ClinOps platform to bring greater efficiency, speed and precision to clinical development and execution."

PhaseV's technology is trusted by over 30 global pharmaceutical and biotech companies as well as CROs, supporting clinical programs in more than 20 therapeutic areas and transforming how trials are designed, conducted, and analyzed.

About PhaseV

PhaseV is developing advanced AI/ML solutions to optimize clinical development. Biopharma sponsors and CROs are leveraging PhaseV's platform to rapidly design and execute adaptive, Bayesian and fixed clinical trials, analyze data to uncover heterogeneous treatment effects, stratify patients, and inform future R&D and portfolio decisions.

Augmented by a robust data lake that integrates high-quality patient-level data, clinical trial results, real-world evidence, and peer-reviewed insights, the platform has demonstrated a reduction in trial costs by 50%, a decrease in enrollment size and trial duration by 40%, and more than 30% increase in the likelihood of trial success.

To date, the company has delivered results for more than 30 leading pharma/biotech sponsors and CROs spanning multiple therapeutic areas, including neurology, oncology, immunology, GI, rare diseases, and others. Learn more at www.PhaseVTrials.com and follow us on LinkedIn. 

Media Contact: 
Ellie Hanson
FINN Partners for PhaseV
[email protected]

Photo: https://mma.prnewswire.com/media/2722727/Melanie_Ivarsson_OBE_PhaseV.jpg
Logo: https://mma.prnewswire.com/media/2267452/PhaseV_logo.jpg

SOURCE PhaseV